APC
FPRX

Aspire Private Capital’s Five Prime Therapeutics, Inc. FPRX Stock Holding History

Aspire Private Capital’s Portfolio FPRX Stock Details FPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-200
Closed -$3K – 627
2020
Q4 		$3K Buy
+200
New +$2.51K ﹤0.01% 368

Other funds holding FPRX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

Aspire Private Capital's FPRX Position: Q1 2021 in Review

Aspire Private Capital sold out of Five Prime Therapeutics, Inc. (FPRX) in Q1 2021, closing a stake of 200 shares — an estimated $3K sold.

Aspire Private Capital first reported a position in FPRX in Q4 2020 and held it in 1 quarter. The position peaked at $3K in Q4 2020. 147 funds tracked by Wall St. Rank hold FPRX as of Q1 2021.

  • Aspire Private Capital reported no remaining Five Prime Therapeutics, Inc. position as of Q1 2021 after selling out during the quarter.
  • Aspire Private Capital sold 200 Five Prime Therapeutics, Inc. shares in Q1 2021, an estimated $3K.
  • Aspire Private Capital first reported a position in Five Prime Therapeutics, Inc. in Q4 2020 and held it in 1 quarter.
  • Aspire Private Capital's Five Prime Therapeutics, Inc. position peaked at $3K in Q4 2020.
  • 147 funds tracked by Wall St. Rank held Five Prime Therapeutics, Inc. as of Q1 2021.

Based on Aspire Private Capital's 13F filing for Q1 2021, filed 26 May 2021.